Author Details

Ulcerative colitis (UC) is a persistent and non-specific sickness appeared typically within the rectum and therefore the entire colon, associated with abnormality of tissue layer towards the resident microorganisms along genital and environmental aspect. Typically presents with bloody diarrhea and is diagnosed by endoscopy and histological findings. Many varieties of medicines are tried to treat tenderness and decrease symptoms. The main aim of management is to induce and maintain remission outlined as resolution of manifestation and scrutiny healing. Herbal drugs add a good vary of remedy compared to western drugs. Though herbal medicines don’t seem to be void of risk, and secure than synthetic drugs. The possible benefits of herbal drugs might exist their huge approval by population owing to its effectiveness, safeness and comparatively lower price. People world wide embraced natural drugs which has been tested in many clinical trials. The evidences on herbal drugs are deficient, complicated and positively related to each risks and benefits there’s a necessity for any controlled clinical trials of the possible effectualness of herbal drugs approaches within the treatment of UC to expand their quality and safety.

Keywords

Herbal Drugs, Tenderness, Remedy, Symptoms, Histological Findings, Ulcerative Colitis.

Full Text

References

Truelove SC et al . Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955; 2(4947):1041-1048.

Travis S et al. European evidence based Consensus on the management of ulcerative colitis: Current management. Journal of Crohns and Colitis. 2008; 2(1):24-62

www.spg.pt/wp-content/uploads/2015/11/2013-UC-management.pdf

https://www.medicalnewstoday.com/articles/163772.php

Sagar Garud and Mark A Peppercorn. Ulcerative colitis: Current Treatment Strategies and Future Prospects. Therapeutic advances in Gastroenterology. 2009 (3): 505-521.

Cornish JA, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103:2394–2400.

Cutolo M, Capellino S, Sulli A, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538–547.

Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95:1949–1954.

Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002;46:1–6.

Berg DJ, Zhang J, Weinstock JV, et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology. 2002;123:1527–1542.

Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.

Basson A. Nutrition management in the adult patient with Crohn’s disease. S Afr J Clin Nutr. 2012;25:164–172.

Russel MG, Engels LG, Muris JW, Limonard CB, Volovics A, Brummer RJ, Stockbrügger RW. Modern life’ in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol. 1998;10:243–249. [

Sakamoto N, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11:154–163.

Chan SS, Luben R, et al. Carbohydrate intake in the etiology of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2014;20:2013–2021.

Reif S, Klein I, Lubin F, et al. Pre-illness dietary factors in inflammatory bowel disease. Gut. 1997;40:754–760.

Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut. 2014;63:776–784.

Tjonneland A, Overvad K, Bergmann MM, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut. 2009;58:1606–1611.

de Silva PS, Luben R, Shrestha SS, Khaw KT, Hart AR. Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries. Eur J Gastroenterol Hepatol. 2014;26:11–18.

Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145:970–977.

Amre DK, D’Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, Israel D, Mack D, Ghadirian P, Deslandres C, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn’s disease in children. Am J Gastroenterol. 2007;102:2016–2025.

Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91–99.

Rossi T, Gallo C, Bassani B, Canali S, Albini A, Bruno A. Drink your prevention: beverages with cancer preventive phytochemicals. Pol Arch Med Wewn. 2014;124:713–722.

El-Tawil AM. Epidemiology and inflammatory bowel diseases. World J Gastroenterol. 2013;19:1505–1507.

Han DY, Fraser AG, Dryland P, Ferguson LR. Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn‘s disease within New Zealand. Mutat Res. 2010;690:116–122.

Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54:1481–1491.

Lerebours E, Gower-Rousseau C, Merle V, et al. Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol. 2007;102:122–131.

Taro Osada, Atsushi Arakawa, Naoto Sakamoto, HiroyaUeyama, Tomoyoshi Shibuya, Tatsuo Ogihara, Takashi Yao, and Sumio Watanabe. Autofluorescence imaging endoscopy for identification and assessment of inflammatory ulcerative colitis, 2011;17(46):5110-6.

https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/diagnosis-treatment/drc-20353331

Hyson DA. A comprehensive review of apples and apple components and their relationship to human health. AdvNutr 2011;2:408‑20.

Boyer J, Liu RH. Apple phytochemicals and their health benefits. Nutr J 2004;3:5.

D’Argenio G, Mazzone G, Tuccillo C, Ribecco MT, Graziani G, Gravina AG, et al. Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. Dig Liver Dis 2012;44:555‑62.

Ulbricht C, Basch E, Basch S, Bent S, Boon H, Burke D, et al. An evidence‑based systematic review of bilberry (Vacciniummyrtillus) by the Natural Standard Research Collaboration. J Diet Suppl 2009;6:162‑200.

Canter PH, Ernst E. Anthocyanosides of Vacciniummyrtillus (bilberry) for night vision‑A systematic review of placebo‑controlled trials. SurvOphthalmol 2004;49:38‑50.

Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak‑Ublick GA, et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis ‑ An open pilot study. J Crohns Colitis 2013;7:271‑9.

Wang LS, Kuo CT, Cho SJ, Seguin C, Siddiqui J, Stoner K, et al. Black raspberry‑derived anthocyanins demethylate tumor suppressor genes through the inhibition of DNMT1 and DNMT3B in colon cancer cells. Nutr Cancer 2013;65:118‑25.

Montrose DC, Horelik NA, Madigan JP, Stoner GD, Wang LS, Bruno RS, et al. Anti‑inflammatory effects of freeze‑dried black raspberry powder in ulcerative colitis. Carcinogenesis 2011;32:343‑50

Andujar I, Recio MC, Giner RM, Cienfuegos‑Jovellanos E, Laghi S, Muguerza B, et al. Inhibition of ulcerative colitis in mice after oral administration of a polyphenol‑enriched cocoa extract is mediated by the inhibition of STAT1 and STAT3 phosphorylation in colon cells. J Agric Food Chem 2011;59:6474‑83.

Maity P, Hansda D, Bandyopadhyay U, Mishra DK. Biological activities of crude extracts and chemical constituents of Bael, Aegle marmelos (L.) Corr. Indian J ExpBiol 2009;47:849‑61

Baliga MS, Bhat HP, Pereira MM, Mathias N, Venkatesh P. Radioprotective effects of Aegle marmelos (L.) Correa (Bael): A concise review. J Altern Complement Med 2010;16:1109‑16

Behera JP, Mohanty B, Ramani YR, Rath B, Pradhan S. Effect of aqueous extract of Aegle marmelos unripe fruit on inflammatory bowel disease. Indian J Pharmacol 2012;44:614‑8.

Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food SciNutr 1997;37:693‑704.

Kim M, Murakami A, Miyamoto S, Tanaka T, Ohigashi H. The modifying effects of green tea polyphenols on acute colitis and inflammation‑associated colon carcinogenesis in male ICR mice. Biofactors 2010;36:43‑51.

Pezzuto JM. Grapes and human health: A perspective. J Agric Food Chem 2008;56:6777‑84.

Sanchez‑Fidalgo S, Sanchez de Ibarguen L, Cardeno A, Alarcon de la Lastra C. Influence of extra virgin olive oil diet enriched with hydroxytyrosol in a chronic DSS colitis model. Eur J Nutr 2012;51:497‑506.

Deshmukh CD, Veeresh B, Pawar AT. Protective effect of Emblica Officinalis fruit extract on acetic acid induced colitis in rats. Journal of Herbal Medicine and Toxicology 2010;4:83‑87

Harris JC, Cottrell SL, Plummer S, Lloyd D. Antimicrobial properties of Allium sativum (garlic). ApplMicrobiolBiotechnol 2001;57:282‑6.

Filocamo A, Nueno‑Palop C, Bisignano C, Mandalari G, Narbad A. Effect of garlic powder on the growth of commensal bacteria from the gastrointestinal tract. Phytomedicine 2012;19:707‑11.

Mukherjee S, Lekli I, Goswami S, Das DK. Freshly crushed garlic is a superior cardioprotective agent than processed garlic. J Agric Food Chem 2009;57:7137‑44.

Harisa GE, Abo‑Salem OM, El‑Sayed el SM, Taha EI, El‑Halawany N. L‑arginine augments the antioxidant effect of garlic against acetic acid‑ induced ulcerative colitis in rats. Pak J Pharm Sci 2009;22:373‑80.

Brahmbhatt M, Gundala SR, Asif G, Shamsi SA, Aneja R. Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. Nutr Cancer 2013;65:263‑72.

Baliga MS, Haniadka R, Pereira MM, D’Souza JJ, Pallaty PL, Bhat HP, et al. Update on the chemopreventive effects of ginger and its phytochemicals. Crit Rev Food SciNutr 2011;51:499‑523.

El‑Abhar HS, Hammad LN, Gawad HS. Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol 2008;118:367‑72.

Srivastava R, Ahmed H, Dixit RK, Dharamveer, Saraf SA. Crocus sativus L.: A comprehensive review. Pharmacogn Rev 2010;4:200‑8.

Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). ExpBiol Med (Maywood) 2002;227:20‑5.

Kamalipour M, Akhondzadeh S. Cardiovascular effects of saffron: An evidence‑based review. J Tehran Heart Cent 2011;6:59‑61.

Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: Pharmacology and clinical uses. Wien Med Wochenschr 2007;157:315‑9.

Kazi HA, Qian Z. Crocetin reduces TNBS‑induced experimental colitis in mice by downregulation of NFkB. Saudi J Gastroenterol 2009;15:181‑7.

Mahendran P, Devi CS. Effect of Garcinia cambogia extract on lipids and lipoprotein composition in dexamethasone administered rats. Indian J PhysiolPharmacol 2001;45:345‑50.

dos Reis SB, de Oliveira CC, Acedo SC, Miranda DD, Ribeiro ML, Pedrazzoli J, Jr., et al. Attenuation of colitis injury in rats using Garcinia cambogia extract. Phytother Res 2009;23:324‑9.

Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. Altern Med Rev 2003;8:20‑7.

Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF‑kappa B‑regulated gene expression. Oncogene 2006;25:1463‑73

Kumar A, Prakash A, Dogra S. Protective effect of curcumin (Curcuma longa) against D‑galactose‑induced senescence in mice. J Asian Nat Prod Res 2011;13:42‑55.

Barzegar A, Moosavi‑Movahedi AA. Intracellular ROS protection efficiency and free radical‑scavenging activity of curcumin. PLoS One 2011;6:e26012

Arafa HM, Hemeida RA, El‑Bahrawy AI, Hamada FM. Prophylactic role of curcumin in dextran sulfate sodium (DSS)‑induced ulcerative colitis murine model. Food ChemToxicol 2009;47:1311‑7.

Deguchi Y, Andoh A, Inatomi O, Yagi Y, Bamba S, Araki Y, et al. Curcumin prevents the development of dextran sulfate Sodium (DSS)‑induced experimental colitis. Dig Dis Sci 2007;52:2993‑8.

Yadav VR, Suresh S, Devi K, Yadav S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti‑inflammatory activity in rat colitis model. AAPS PharmSciTech 2009;10:752‑62.

Yadav VR, Suresh S, Devi K, Yadav S. Novel formulation of solid lipid microparticles of curcumin for anti‑angiogenic and anti‑inflammatory activity for optimization of therapy of inflammatory bowel disease. J Pharm Pharmacol 2009;61:311‑21.

Liu L, Liu YL, Liu GX, Chen X, Yang K, Yang YX, et al. Curcumin ameliorates dextran sulfate sodium‑induced experimental colitis mice by downregulation of NFkB. Saudi J Gastroenterol 2009;15:181‑7. YX, et al. Curcumin ameliorates dextran sulfate sodium‑induced experimental colitis by blocking STAT3 signaling pathway. IntImmunopharmacol 2013;17:314‑20.

Salh B, Assi K, Templeman V, Parhar K, Owen D, Gomez‑Munoz A, et al. Curcumin attenuates DNB‑induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003;285:G235‑43.

Venkataranganna MV, Rafiq M, Gopumadhavan S, Peer G, Babu UV, Mitra SK. NCB‑02 (standardized Curcumin preparation) protects dinitrochlorobenzene‑ induced colitis through down‑regulation of NFkappa‑B and iNOS. World J Gastroenterol 2007;13:1103‑7.

Camacho‑Barquero L, Villegas I, Sanchez‑Calvo JM, Talero E, Sanchez‑Fidalgo S, Motilva V, et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX‑2 and iNOS expression in chronic experimental colitis. IntImmunopharmacol 2007;7:333‑42.

Jiang H, Deng CS, Zhang M, Xia J. Curcumin‑attenuated trinitrobenzenesulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase‑2. World J Gastroenterol 2006;12:3848‑53.

Larmonier CB, Uno JK, Lee KM, Karrasch T, Laubitz D, Thurston R, et al. Limited effects of dietary curcumin on Th‑1 driven colitis in IL‑10 deficient mice suggest an IL‑10‑dependent mechanism of protection. Am J Physiol Gastrointest Liver Physiol 2008;295:G1079‑91.

Ung VY, Foshaug RR, MacFarlane SM, Churchill TA, Doyle JS, Sydora BC, et al. Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti‑inflammatory effect in the IL‑10 gene‑deficient mouse model of IBD. Dig Dis Sci 2010;55:1272‑7.

Baliga MS, Joseph N, Venkataranganna MV, Saxena A, Ponemone V, Fayad R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: Preclinical and clinical observations. Food Funct 2012;3:1109‑17.

Nones K, Dommels YE, Martell S, Butts C, McNabb WC, Park ZA, et al. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene‑deficient (mdr1a‑/‑) mice, a model of inflammatory bowel diseases. Br J Nutr 2009;101:169‑81.

Assessment of Inflammatory Bowel Disease and its Herbal Cure:A Review

Abstract Views :206 | PDF Views:0

Authors

Prerna Dubey ¹, M. Sumithra ¹, V. Chitra ¹

Affiliations
1 Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur 603203, Tamil Nadu, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 3 (2019), Pagination: 1432-1440

Abstract

Inflammatory bowel diseases (IBD) termed as chronic inflammatory disorders of the gastrointestinal tract distinct by episodes of reversion and decline. The two identified subtypes of the disease, ulcerative colitis and Crohn's Disease which differ in forms of clinical presentation. Environmental factors, including infections, diet, lifestyle factors, medication use have contributed to alterations in the global prevalence of the disease. Although the exact pathogenesis of IBD remains unknown, part of the underlying mechanism is a deregulated host immune response to intestinal flora, in genetically vulnerable Beings. The incidence of IBD is persistently rising in other earlier low incidence areas, such as Asia and the developing world. The annual frequency of CD is highest in North America (20.2 per 100,000, per person-years); whereas the annual occurrence of UC is highest in Europe (24.3 per 100,000 per person-years) Environmental risk factors of IBD is smoking, air water pollution, vitamin D, dietary, NSAID, stress. The newly described Th17 cells are also involved in the gut inflammatory answer in IBD. To understand the pathogenesis of IBD alternative model has been used such as zebrafish, c. elegans, Drosophila. The novel treatment of IBD such as vedolizumab, Etrolizumab, agents targeting specific pathways in IBD, but unfortunately possess life-threatening adverse effect and globally increased cost. This review also focuses on the favourable results from the use of herbal products in the treatment of IBD.

Keywords

Ulcerative, Colitis, Crohn’s, Antioxidant, Vedolizumab, Pathogenesis.

Full Text

References

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728155/

Ahuja V, Tandon RK: Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol 201231: 294–296.

Russell RK, Satsangi J. Does IBD run in families? Inflamm Bowel Dis 2008; 14 Suppl 2: S20-S21 [PMID: 18816757 DOI: 10.1002/ IBD.20573]

Ek WE, D'Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. Ann Gastroenterol 2014; 27: 294-303 [PMID: 25331623]

Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142:46–54 e42; quiz e30.

Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011; 17:423–439

Malmborg P, Grahnquist L, Lindholm J, Montgomery S, Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in Northern Stockholm County 2002–2007. J PediatrGastroenterolNutr. Epub March 1, 2013.

Grieci T, Butter A. The incidence of inflammatory bowel disease in the pediatric population of Southwestern Ontario. J Pediatr Surg. 2009;44: 977–980.

Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J GastroenterolHepatol. 2012;27:1266–1280.

Ahuja V, Tandon RK: Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol 2012; 31: 294–296.

Ng SC, Tang W, Ching JY, et al.; Asia-Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group: rate and phenotype of inflammatory bowel disease based on results outcome from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 2013; 145: 158–165.

Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment PharmacolTher 2005; 21: 921-931 [PMID: 15813828 DOI: 10.1111/j.1365-2036.2005.02424.x]

Hu D, Ren J, Wang G, Gu G, Liu S, Wu X, Chen J, Ren H, Hong Z, Li J. Geographic mapping of Crohn's disease and its relation to affluence in Jiangsu province, an eastern coastal province of China. Gastroenterol Res Pract 2014; 2014: 590467 [PMID: 24839438 DOI: 10.1155/2014/590467]

Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, Wheeler AJ, Villeneuve PJ. The inflammatory bowel disorder and ambient air pollution: a new organisation. Am J Gastroenterol 2010; 105: 2412-2419 [PMID: 20588264 DOI: 10.1038/ajg.2010.252]

Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T, MacDonald PN. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. MolEndocrinol 2000; 14: 421-428 [PMID: 10707959 DOI: 10.1210/ mend.14.3.0424]

Wagner M, Schlüsener MP, Ternes TA, Oehlmann J. Identification of putative steroid receptor antagonists in bottled water: combining bioassays and high-resolution mass spectrometry. PLoS One 2013; 8:

Wagner M, Schlüsener MP, Ternes TA, Oehlmann J. Identification of putative steroid receptor antagonists in bottled water: combining bioassays and high-resolution mass spectrometry. PLoS One 2013; 8:

Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T, MacDonald PN. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. MolEndocrinol 2000; 14: 421-428 [PMID: 10707959 DOI: 10.1210/ mend.14.3.0424]

Vedani A, Smiesko M, Spreafico M, Peristera O, Dobler M. VirtualToxLab - in silico prediction of the toxic (endocrine disrupting) potential of drugs, chemicals and natural products. Two years and 2,000 compounds of experience: a progress report. ALTEX 2009; 26: 167-176 [PMID: 19907904]

Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. ExpBiol Med (Maywood) 2004; 229: 1136-1142 [PMID: 15564440]

Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxy vitamin D3, and the immune system. Am J ClinNutr 2004; 80: 1717S-1720S [PMID 15585793]

Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT. Higher predicted vitamin D status associated with reduced risk of Crohn's disease. (Gastroenterology 2012) 142: 482-489 [PMID: 22155183 DOI: 10.1053 /j.gastro. 2011.11.040]

Khalili H, Huang ES, Ananthakrishnan AN, Higuchi L, Richter JM, Fuchs CS, Chan AT. Geographical variation and rate of inflammatory bowel disease among US women. Gut 2012; 61: 1686-1692 [PMID: 22241842 DOI: 10.1136/gutjnl-2011-301574] 63 Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519 [PMID: 12583961 DOI: 10.1016/ s0140-6736(03)12489-0]

Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. A function of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 137-151 [PMID: 19462428 DOI: 10.1002 /IBD. 20968]

Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011; 106: 563-573 [PMID: 21468064 DOI: 10.1038/ajg.2011.44]

Ma X, Torbenson M, Hamad AR, Soloski MJ, Li Z. High-fat diet modulates non-CD1d-restricted natural killer T cells and regulatory T cells in mouse colon and exacerbates experimental colitis. ClinExpImmunol 2008; 151: 130-138 [PMID: 17991290 DOI: 10.1111/ j.1365-2249.2007.03530.x]

Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-induced taurocholic acid stimulates pathobiont expansion and colitis in Il10-/- mice. Nature 2012; 487: 104-108 [PMID: 22722865 DOI: 10.1038/nature11225]

Bassaganya-Riera J, DiGuardo M, Viladomiu M, de Horna A, Sanchez S, Einerhand AW, Sanders L, Hontecillas R. Soluble fibres and resistant starch improve disease activity in interleukin-10deficient mice with inflammatory bowel disease. J Nutr 2011; 141: 1318-1325 [PMID: 21562241 DOI: 10.3945/jn.111.139022]

Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT. A prospective study of long-term intake of dietary fibre and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013; 145: 970-977 [PMID: 23912083 DOI: 10.1053/j.gastro.2013.07.050]

Ayokunle T Abegunde, Tauseef Ali, Section of Digestive Diseases and Nutrition, Department of Medicine, Oklahoma University Health Sciences Center, Oklahoma City, OK 73104, United States

Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The anxiety response and the regulation of inflammatory disease. Ann Intern Med 1992; 117: 854-866 [PMID: 1416562]

Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010; 105: 1994-2002 [PMID: 20372115 DOI: 10.1038/ajg.2010.140]

Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006; 367: 1271-1284 [PMID: 16631883 DOI: 10.1016/S0140-6736(06)68345-1]

Duerr RH. Genome-wide association studies herald a new era of quick discoveries in inflammatory bowel disease research. Gastroenterology 2007; {132: 2045-2049} [PMID: 17484895 DOI: 10.1053/j.gastro.2007.03.082]

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A Boucher G, Brand S, Büning C, Cohain A, Cichon S, D' Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. (Nature 2012; 491: 119-124) [PMID: 23128233 DOI: 10.1038/nature11582]

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606 [ PMID: 11385577 DOI: 10.1038/35079114]

Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. The Implications for Crohn's disease. J BiolChem 2003; 278: 5509-5512 [PMID: 12514169 DOI: 10.1074/jbc. C200673200]

Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-97 [PMID: 19966812 DOI: 10.1038/nm. 2069]

Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG, Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62 [PMID: 19898471 DOI: 10.1038/ni. 1823]

Shaw MH, Kamada N, Warner N, Kim YG, Nuñez G. The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation. Trends Immunol 2011; 32: 73-79 [ PMID: 21251876 DOI: 10.1016/j.it.2010.12.007]

Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009; 10: 1073-1080 [ PMID: 19701189 DOI: 10.1038/ni. 1782]

Franke A, McGovern DP, Barrett JC, Wang K, RadfordSmith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn' s disease susceptibility loci. Nat Genet 2010; 42: 1118-1125 [PMID: 21102463 DOI: 10.1038/ng.717]

Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide organization study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596-604 [PMID: 17435756 DOI: 10.1038/ng2032]

McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, Xavier RJ. Deletion polymorphism was upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008; 40: 1107-1112 [PMID: 19165925 DOI: 10.1038/ng.215]

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired autophagy of an intracellular pathogen-stimulated by a Crohn' s disease associated ATG16L1 variant. PLoS One 2008; 3: e3391 [PMID: 18852889 DOI: 10.1371/journal.pone.0003391

Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463 [PMID: 17068223 DOI: 10.1126/science.1135245]

Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, PeyrinBiroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252 [PMID: 21297633 DOI: 10.1038 /ng. 764]

Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009; 58: 1152-1167 [PMID: 19592695 DOI: 10.1136/ gut.2008.163667]

Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res ClinGastroenterol 2004; 18: 481-496 [PMID: 15157822 DOI: 10.1016 /j.bpg. 2003.12.003]

Cosnes J. What is the relation between the use of tobacco and IBD? Inflamm Bowel Dis 2008; 14 Suppl 2: S14-S15 [PMID: 18816683 DOI: 10.1002/ibd. 20555]

Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007; 13: 6134-6139 [PMID: 18069751]

Birrenbach T, Böcker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004; 10: 848-859 [PMID: 15626903]

Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR. Review article: vitamin D and inflammatory bowel disease-established concepts and future directions. Aliment PharmacolTher 2012; 36: 324-344 [PMID: 22686333 DOI: 10.1111/ j.1365-2036.2012.05181.x]

Cobrin GM, Abreu MT. Defects in mucosal immunity foremost to Crohn's disease. Immunol Rev 2005; 206: 277-295 [PMID: 16048555 DOI: 10.1111/j.0105-2896.2005.00293.x]

Targan SR, Karp LC. Defects in mucosal immunity foremost to ulcerative colitis. Immunol Rev 2005; 206: 296-305 [PMID: 16048556 DOI: 10.1111/j.0105-2896.2005.00286.x]

Geremia A, Jewell DP. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2012; 6: 223-237 [PMID: 22375527 DOI: 10.1586/egh.11.107]

Janelle A. Jiminez, Trina C. Uwiera, G. Douglas Inglis and Richard R. E. Uwiera The animal model to study acute and chronic intestinal inflammation in mammals; gut pathogens 17-19 Received: 14 September 2015 Accepted: 22 October 2015[DOI 10.1186/S13099-015-0076-y

Narula N, Rubin DT, Sands BE. The novel treatment for inflammatory bowel disease: an evaluation of the data. Am J Gastroenterol Suppl 2016; 3:38-44.

Hyo Sun Lee, Soo-Kyung Park, and Dong Il Park Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Received: November 28, 2017, Accepted: December 4, 2017

H. Sies, Oxidative stress: a concept in redox biology and medicine, Redox Biol. C 4 (2015) 180–183, http://dx.doi.org/10.1016/j.redox.2015.01.002

S.M.L. Vasconcelos, M.O.F. Goulart, J.B. d F. Moura, V.M. e M. d S. Benfato, L.T. Kubota, Espéciesreativas de oxigênio e de nitrogênio, antioxidantes e marcadores de danooxidativoemsanguehumano: principaismétodosanalíticos para suadeterminação, Quim. Nova 30 (5) (2007) 1323–1338.

A. Bhattacharyya, R. Chattopadhyay, S. Mitra, S.E. Crowe, Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases, Physiol. Rev. 94 (2) (2014) 329–354, http://dx.doi.org/10.1152/ physrev.00040.2012.

M. Amasheh, I. Grotjohann, S. Amasheh, A. Fromm, J.D. Söderholm, M. Zeitz, M. Fromm, J.-D. Schulzke, Regulation of mucosal structure and barrier function in rat colon exposed to tumour necrosis factor alpha and interferon gamma in vitro: a novel model for studying the pathomechanisms of inflammatory bowel disease cytokines, Scand. J. Gastroenterol. 44 (10) (2009) 1226–1235, http://dx.doi.org/10.1080/00365520903131973

N. Kannan, C. Guruvayoorappan, Protective effect of Bauhinia tomentosa on acetic acid-induced ulcerative colitis by regulating antioxidant and inflammatory mediators, Int. Immunopharmacol. 16 (1) (2013) 57–66, HTTP://dx.doi.org/10.1016/j.intimp.2013.03.008.

P.P. Trivedi, G.B. Jena, Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: investigation on possible mechanisms, Dig. Dis. Sci. 58 (12) (2013) 3460–3474, http://dx.doi.org/10.1007/ s10620-013-2831-6.

https://www.google.co.in/search?q=ulcerative+colitis+images&source=lnms&tbm=isch&sa=X&ved=0ahUKEwizocrSrOLcAhWLbysKHXgvA_UQ_AUICigB&biw=1536&bih=711&dpr=1.25#imgrc=iDvTsiF7rYnWeM:

https://www.google.co.in/search?biw=1536&bih=711&tbm=isch&sa=1&ei=pXJtW8K9EtrerQHI8qXIDg&q=crohn%27s+disease+images&oq=croh+images&gs_l=img.1.0.0i7i30k1l10.35122.38598.0.40535.22.12.0.0.0.0.328.1471.1j6j1j1.9.0....0...1c.1.64.img.6.6.1144...0j0i8i7i30k1j0i67k1.0.dx3MAv1Zk44#imgrc=rU1014D3DFRUOM:

Marc Fakhoury,Rebecca Negrulj,Armin Mooranian, and Hani Al-Salami, Inflammatory bowel disease: clinical aspects and treatments, Journal of inflammation research, 2014; 7: 113–120.

John K. Triantafillidisa, Aikaterini Triantafyllidia, Constantinos Vagianosb, Apostolos Papaloisc Favorable results from the use of herbal and plant products inflammatory bowel disease: evidence from experimental animal studies Annals of Gastroenterology (2016) 29, 268-281.

Targets for Alzheimer’s Disease

Abstract Views :161 | PDF Views:0

Authors

S. Dhinakaran ¹, T. Tamilanban ¹, V. Chitra ¹

Affiliations
1 Department of Pharmacology, SRM College of Pharmacy, SRM Institution of Science and Technology, Kattangulathur – 603203, Tamil Nadu, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 6 (2019), Pagination: 3073-3077

Abstract

AD is predominant of causing mortality across the world. Various type of hallmarks has been exploring in this disease, like aggregates of β-amyloid, hyperphosphorylated tau proteins, dyshomeostasis of biometals, oxidative stress, reduction in Ach, etc. There is no test to diagnose AD and it not simple. The majority of putative disease-modifying treatments in development for Alzheimer's disease directed against the amyloid-β (A β) peptide. AD allowed for the development of the first generation of therapies that are somewhat specific for this disorder. Acetylcholine esterase, β-secretase, tau protein and NMDA are the essential targets involves in the treatment of Alzheimer’s disease. AChE inhibitors and NMDA blockade have proven that higher efficacy levels in AD and many authors considering that as "symptomatic" treatments.

Keywords

Alzheimer’s Diseases, β-Amyloid, Acetylcholine, A Cholinesterase Inhibitor, NMDA.

Full Text

References

Alzheimer’s A. 2015 Alzheimer's disease facts and figures. Alzheimer's and dementia: the journal of the Alzheimer's Association. 2015 Mar; 11(3):332.

Sanmugam K. Depression is a risk factor for Alzheimer disease-review. Research Journal of Pharmacy and Technology. 2015 Aug 1; 8(8):1056.

Derflinger S, Sorg C, Gaser C, Myers N, Arsic M, Kurz A, Zimmer C, Wohlschläger A, Mühlau M. Grey-matter atrophy in Alzheimer's disease is asymmetric but not lateralized. Journal of Alzheimer's Disease. 2011 Jan 1; 25(2):347-57.

Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Archives of neurology. 2011 Sep 1; 68(9):1124-30.

Corona C, Pensalfini A, Frazzini V, Sensi SL. New therapeutic targets in Alzheimer's disease: brain deregulation of calcium and zinc. Cell death and disease. 2011 Jun; 2(6):e176.

Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, Sánchez-Benavides G, Huesa G, Morán S, Dal-Ré R, Camí J. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2016 Jun 1; 2(2):82-92.

Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017 Sep 1; 3(3):367-84.

Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alzheimer's research & therapy. 2016 Dec; 8(1):39.

Culter NR, Sramek JJ. Review of the nest generation of Alzheimer's disease therapeutics: challenges for drug development [J]. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25(1):27-57.

Coman H, Nemeş B. New therapeutic targets in Alzheimer's disease. International Journal of Gerontology. 2017 Mar 1; 11(1):2-6.

https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447

Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Frontiers in aging neuroscience. 2014 Jul 29; 6:171.

Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K, Gupta N, Nair P, Tripathi T, Kumar A. Current and novel therapeutic molecules and targets in Alzheimer's disease. Journal of the Formosan Medical Association. 2016 Jan 1; 115(1):3-10.

Stahl SM, Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press; 2013 Apr 11.

Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001 Oct 25; 32(2):177-80.

Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimer's and dementia. 2013 Mar 1; 9(2):208-45.

Orejarena-Ballestas MC, Quiñonez-Pérez AM, Marín-Gutiérrez A. Estimulación cognitiva para pacientes con trastorno neurocognitivo mayor por enfermedad de alzheimer: revisión sistemática. Búsqueda. 2017 Dec 15; 4(19):208-26.

Crouch PJ, Barnham KJ. Therapeutic redistribution of metal ions to treat Alzheimer’s disease. Accounts of chemical research. 2012 Jun 29; 45(9):1604-11.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine. 2016 Jun 1; 8(6):595-608.

Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, Basun H, Lannfelt L. Safety and tolerability of BAN2401-a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer's research and therapy. 2016 Dec; 8(1):14.

Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert opinion on biological therapy. 2012 Aug 1; 12(8):1077-86.

Zhang HY, Yan H, Tang XC. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cellular and Molecular Neurobiology. 2008 Feb 1; 28(2):173-83.

Raghubabu K, Swarup LS, Ramu BK, Rupakumari G, Narayanarao M, Ramdas C. Development and Validated Visible Spectrophotometric Methods for the Assay of Donepezil hydrochloride in Pharmaceutical preparations. Research Journal of Pharmacy and Technology. 2012 Feb 1; 5(2):228.

Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. International Journal of Neuropsychopharmacology. 2006 Feb 1; 9(1):101-24.

Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Current neuropharmacology. 2013 May 1; 11(3):315-35.

Lalut J, Santoni G, Karila D, Lecoutey C, Davis A, Nachon F, Silman I, Sussman J, Weik M, Maurice T, Dallemagne P. Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase. European journal of medicinal chemistry. 2019 Jan 15; 162:234-48.

Sehgal SA, Hammad MA, Tahir RA, Akram HN, Ahmad F. Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. Current neuropharmacology. 2018 Jul 1; 16(6):649-63.

Lichtenthaler SF. Alpha‐secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential. Journal of neurochemistry. 2011 Jan; 116(1):10-21.

Vincent B, Checler F. α-Secretase in Alzheimer's disease and beyond: mechanistic, regulation and function in the shedding of membrane proteins. Current Alzheimer Research. 2012 Feb 1; 9(2):140-56.

Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, Tüscher O, Fellgiebel A. Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. Neurology. 2014 Nov 18; 83(21):1930-5.

Olariu A, Yamada K, Nabeshima T. Amyloid pathology and protein kinase C (PKC): possible therapeutics effects of PKC activators. Journal of pharmacological sciences. 2005; 97(1):1-5.

Mancini F, De Simone A, Andrisano V. Beta-secretase as a target for Alzheimer’s disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Analytical and bioanalytical chemistry. 2011 Jun 1; 400(7):1979-96.

Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochimica et Biophysica Acta (BBA)-General Subjects. 2008 May 1; 1780(5):819-25.

Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. The Lancet Neurology. 2014 Mar 1; 13(3):319-29.

Menting KW, Claassen JA. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease. Frontiers in aging neuroscience. 2014 Jul 21; 6:165.

Pai V, Chandrashekar KS, Shreedhara CS, Pai A. In-Silico and In-Vitro correlation studies of natural β-secretase inhibitor: An approach towards Alzheimer's Disease. Research Journal of Pharmacy and Technology. 2017 Oct 1; 10(10):3506-10.

Ghosh AK, Brindisi M, Tang J. Developing β‐secretase inhibitors for treatment of Alzheimer’s disease. Journal of neurochemistry. 2012 Jan 1; 120:71-83.

Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine. 2003 Apr 3; 348(14):1333-41.

Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer’s disease. CNS drugs. 2003 Aug 1; 17(9):641-52.

Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological Reports. 2015 Apr 1; 67(2):195-203.

Shahnawaz Khan M, Amjad Kamal M, Tabrez S. Elucidating treatment of Alzheimer's Disease via different receptors. Current topics in medicinal chemistry. 2017 May 1; 17(12):1400-7.

Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. Journal of neural transmission. 2014 Aug 1; 121(8):799-817.

López LM, López EA, González CV, inventors; Universidade de Santiago de Compostela, assignee. Use of a spirolide, analogues and derivatives for treating and/or preventing pathological conditions linked to the tau and beta-amyloid proteins. United States patent application US 13/500, 018. 2012 Oct 11.

Reddy AR, Venkateswarulu TC, Indira M, Narayana AV, Lohita TN, Sriharsha M. Identification of Membrane Drug Targets by Subtractive Genomic Approach in Mycoplasma Pneumonia. Research Journal of Pharmacy and Technology. 2015 Sep 1; 8(9):1209.

Froestl W, Pfeifer A, Muhs A. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. Journal of Alzheimer's Disease. 2013 Jan 1; 34(1):1-14.

M. Vijey Aanandhi, Niventhi. A, Rujaswini. T, Hemalatha C.N, Praveen. D. A Comprehensive Review on the Role of Tau Proteins in Alzheimer’s Pathology. Research Journal of Pharmacy and Technology 2018; 11(2):788-790.

Martin-Rapun R, De Matteis L, Ambrosone A, Garcia-Embid S, Gutierrez L, M de la Fuente J. Targeted Nanoparticles for the Treatment of Alzheimer's Disease. Current pharmaceutical design. 2017 Apr 1; 23(13):1927-52.

Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in molecular medicine. 2009 Mar 1; 15(3):112-9.

Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, Matt L, Hell JW, Wisely EV, Oddo S, Xiang YK. β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer's disease models. Journal of Biological Chemistry. 2013 Feb 19:jbc-M112.

Pandey A, Pawar MS. Assessment of Nootropic Activity of Panchagavya Ghrita in Animal Models. International Journal of Scientific and Research Publications. 2015 Aug; 5(8):1-5.

Mishra P, Maurya RK, Dwivedi D. Effect of Dopamine on Alzheimer and Autism and Determination of Best Model Organism for Both.

Jindal V. Glaucoma A multifactorial disease and its multidimensional management. International Journal of Scientific and Research Publications. 2013; 3:1-3.

Pandey A, Pawar MS. Assessment of Nootropic Activity of Panchagavya Ghrita in Animal Models. International Journal of Scientific and Research Publications. 2015 Aug; 5(8):1-5.

Swathi GS. Death anxiety, death depression, geriatric depression and suicidal ideation among institutionalized and noninstitutionalized elders. International Journal of Scientific and Research Publications. 2014 Oct; 4(10):356-64.

Auti MS, Hulle NB. Advanced shoes with embedded position tracking and path guidance to keep track of Alzheimer’s patients. International Journal of Scientific and Research Publications. 2015; 5(1).

Ibrahim N, Aziz HA. Trends on natural organic matter in drinking water sources and its treatment. International Journal of Scientific Research in Environmental Sciences. 2014 Mar 1; 2(3):94.

Krishnapriya R, Padmaja M. Study on individual and combined toxicity of quinalphos and dimethoate on certain neurological aspects of giant fresh water prawn Macrobrachium rosenbergii (Deman, 1879). International Journal of Scientific and Research Publications. 2014; 4:1-5.

Sivapalan SR. Medicinal uses and pharmacological activities of Cyperus rotundus Linn-A Review. International Journal of Scientific and Research Publications. 2013 May; 3(5):1-8.

Reddy CB, Reddy GS, Reddy NA. Development and validation of UV spectrophotometric method for determination of trifluoperazine hydrochloride in bulk and pharmaceutical dosage form. International Journal of Scientific and Research Publications. 2012 Aug; 2(8):1-5.

Username
Password
Remember me